Chlorhexidine and the control of plaque and gingivitis

Van Strydonck, D.A.C.

Publication date
2013

Citation for published version (APA):
Chapter 6

The clinical efficacy of a chlorhexidine-delivering toothbrush

Van Strydonck D. A. C.
Timmerman M. F.
Van der Velden U.
Van der Weijden G. A

Department of Periodontology, Academic Centre for Dentistry Amsterdam, The Netherlands

Journal of Clinical Periodontology 2008, 35: 584-590
Introduction

The importance of oral hygiene in the prevention of caries and periodontal disease has been extensively demonstrated (Löe et al. 1965, Axelsson et al. 1991). The most reliable methods currently used for plaque control are mechanical cleaning using a toothbrush (for review see Hancock 1996) and a range of interproximal devices. In order to achieve efficiency by mechanical methods only, individual motivation and high standards of skill are required, and in the interdental spaces, where the highest prevalence of marginal gingivitis occurs, efficient tooth brushing alone still has only a limited effect (Löe et al. 1965, Gjermo & Flötra 1970). Furthermore, meticulous dental cleaning is a time-consuming procedure.

Chemotherapeutic agents have the potential to inhibit plaque growth, reduce gingivitis and improve oral health beyond tooth brushing alone (Addy & Moran 1997). As an effective antibacterial agent, chlorhexidine (CHX) still remains the gold standard, unsurpassed by other agents (Gjermo et al. 1970, Addy 1986, Paraskevas 2005). The method of CHX application, however, seems to be important for its effect on the bacterial flora (Emilson & Fornell 1976, Bay 1978). Four methods of application with various CHX concentrations are available for the user: a fluid (0.2%, 0.12%), a gel (1% and 0.5%), a dentifrice (0.12%), a spray (0.12%).

A new design of toothbrush was developed for the present study. This brush contains a template within the brush head, which releases CHX when brought into contact with oral fluids (Fig 1). This delivery system may provide the benefits of reduced plaque and gingivitis beyond toothbrushing alone, while also diminishing the negative side effects of traditional CHX therapy, and additionally enhancing users’ oral hygiene. The purpose of this study was to test whether a manual toothbrush with a slow release system of CHX is safe and more effective in inhibiting plaque and gingival bleeding following 6 weeks of use. A secondary objective was to assess the amount of stain on the teeth.
Materials and methods

Subjects
A total of one hundred and fifty (n=150) subjects, between 18 and 65 years of age, were selected on the basis of good general health, and no medical or dental history or medication, which might interfere with the outcome or progress of the study. The participants were non-dental students at the University of Amsterdam, The Netherlands. Subjects were eligible for the study if they had a minimum of 18 scorable natural teeth, excluding third molars or crowned teeth with porcelain or gold restorations. To be enrolled in the study, the subjects were required to have a minimum of 40% bleeding sites as determined by the Bleeding on Marginal Probing Index (BOMP, Van der Weijden et al.1994).

Subjects were excluded if they had any physical limitations or restrictions, which might preclude normal toothbrushing skills. They were also excluded if they had used an oral CHX product or taken a systemic antibiotic or anti-inflammatory drug for three consecutive days within the previous 3 months. Subjects with removable prostheses or orthodontic appliances were not allowed to participate.

All eligible subjects were given oral and written information about the products and the purpose of the study. After screening for suitability, they were requested to give their written informed consent to qualify for enrolment. The study was approved by the Medical Ethic Committee of the Amsterdam Medical Center (MEC 98/139).

Description of study materials
The toothbrushes for this clinical study had a straight handle and soft, round-ended bristles. The toothbrushes were produced at Oral-B Laboratories using the same trim filament pattern as the commercially available Oral B Advantage 40 Soft brush. However, the brush head was slightly larger and hollow to accommodate the template of freeze-dried CHX. Three tufts of bristles in the middle brush section were excluded to permit capillary movement of CHX along the tufts of the bristles thereby allowing a slow CHX release while brushing (Fig 1). Study materials were maintained under secure, dry, room temperature conditions until assigned to subjects.
The template toothbrush (Fig 1A & Fig 1B)

Fig 1A

Fig 1B

The total amount of CHX digluconate in each test toothbrush was approximately 124 mg. In vitro testing (data on file) showed that the average release per brushing was 1.3 mg. The maximum release per brushing (60 seconds) was 5.04 mg CHX, which occurred after the 2nd brushing. The release profile dropped below the average after 23 brushings and fell after 40 brushings to 0.19 mg. After 42 brushings, 45.3% of the CHX digluconate had been released from the template.
Procedure
This study was 3-cell longitudinal, examiner-blind, randomized, controlled, parallel designed study of 6 weeks duration. Randomization was performed using a computer generated list of random numbers. Study products were coded and distributed to the subjects in a location away from the examiners to ensure and maintain blinding. The examiners were blind to treatment randomization and records of earlier examinations were not available at time of re-examinations. The study coordinator was responsible for allocation concealment. One examiner assessed all plaque scores (Silness & Løe 1964, Danser et al. 2003) and performed all stain evaluations on the buccal surfaces of all scorable teeth using the Gründemann Modified Stain Index (GMSI, Gründemann et al. 2000). Another examiner assessed all bleeding scores using the Bleeding on Marginal Probing Index (BOMP, Saxton & Van der Ouderaa 1989, Van der Weijden et al. 1994) and all safety evaluations. Both examiners (M. Piscaer & Y. IJzerman) were well-trained and had been involved in previous studies.

Baseline
At baseline subjects received a supragingival prophylaxis to render them plaque and stain free. They were randomly assigned to one of the three following treatment groups:

- **Template Test Brush (Ttb):** the manual experimental toothbrush with a template slow-releasing delivery system of 124 mg CHX digluconate (see Fig. 1).
- **Template Control Brush (Ctb):** the same toothbrush as the template test brush (Ttb), without CHX digluconate, which was the negative control (see Fig 1)
- **Template Control Brush + CHX rinse (Ctb+R):** the template toothbrush without CHX digluconate plus twice daily rinsing with a commercially available 0.2% CHX digluconate mouthrinse, which was the positive control (Corsodyl® GlaxoSmithKline, Zeist, the Netherlands).

All subjects were provided with written instructions for their assigned products. Subjects in the Ttb and the Ctb group were instructed to brush twice daily without dentifrice during one minute (in the morning and the evening), using only their assigned products. Subjects in the Ctb+R group were instructed to brush twice daily without dentifrice, and to rinse afterwards for 60 seconds with 10 ml of 0.2% CHX digluconate mouthrinse (Corsodyl®). To monitor compliance,
subjects were given a brushing diary and instructed to record each day the time of their tooth-
brushing and/or toothbrushing plus rinsing. In addition, all mouthrinse bottles were weighed
before distribution. Throughout the duration of the study, subjects were asked to refrain from
rinsing, eating or drinking for 30 minutes after using their assigned product. They were asked
to refrain from all forms of oral hygiene for 12 to 18 hours prior to their baseline, interim
(3 weeks) and final (6 weeks) visits and to bring their randomly assigned (test) toothbrush,
mouthrinse (if applicable) and diary.

**Interim examination**

At study week 3, each subject was scheduled for an interim examination. During this visit,
subjects were asked about changes in their medical and dental histories, and concomitant
medications, and adverse events were reviewed. Assessments of oral tissues, plaque, and
bleeding on marginal probing were performed. In addition, staining was assessed. Used
toothbrushes were collected and replaced by fresh brushes. Returned mouthrinse bottles
and fresh mouthrinse bottles (before distribution) were weighed. All brushing diaries were
evaluated for compliance and returned to subjects. The subjects were reminded to refrain
from using assigned products for 12 to 18 hours prior to their final examination and to bring
with them their randomly assigned (test) toothbrush, mouthrinse (if applicable) and brushing
diary.
**Final examination**

The outline of this last visit was identical to the interim examination. Upon completion subjects returned the assigned products and ended the study.

**Data analysis**

Using variability estimates from a previous study (Van der Weijden et al. 1994) power curves were examined to indicate the number of subjects needed to detect statistically significant treatment differences in the BOMP index. Based on these data, assuming a constant variability of $\sigma = 0.775$ and $\alpha = 0.05$, a sample size of 45 subjects per treatment group was needed to ensure an 80% (power = 1-ß) or greater chance of detecting differences of ≤0.11 whole mouth BOMP units.

Full-mouth mean plaque (MSLPI), bleeding (BOMP) and stain (GMSI) scores were calculated. Plaque and bleeding scores were considered as the primary efficacy variables and stain (GMSI) as a secondary variable. $p$-values ≤ 0.05 were considered as statistically significant. Within each treatment group, a Wilcoxon test was used to compare means of each of the three scores at the interim and final time points in order to assess treatment effects across time. Kruskal–Wallis, with post-testing corrected for multiple comparisons, was used to analyze the differences in plaque, bleeding and staining between the three regimens.

Oral tissue data were summarized by tabulating the frequency and percentage of abnormal observations. Oral tissue observations within a treatment group were examined to assess the safety of treatments across time using McNemar’s test. Differences between treatments were determined by comparing the distributions of abnormal findings in each treatment group utilizing the chi-square test for homogeneity.

**Results**

A total of 150 subjects meeting the inclusion criteria were recruited and enrolled into the study. After having signed the informed consent they were randomly divided to 3 groups of 50 subjects each. At the baseline assessment 10 subjects disqualified for personal reasons, such as vacation, or for medical reasons, such as the use of antibiotics or CHX. No data were obtained for these subjects and they were therefore not included in the data analysis. 140 subjects completed the study and were included in the “Intention to treat analysis” (Fig.2).
No adverse events were reported. Demographic data for the 3 treatment groups (n=140) are shown in Table 1. Treatment group Ttb had a population size of 46 subjects, while treatment groups Ctb and Ctb+R had 47 subjects. There was no statistically significant difference in mean age detected among the groups (23, 22 and 21 years, respectively). At baseline no significant differences were detected among the treatment groups with respect to mean whole mouth plaque and gingival bleeding levels.
Table 1. Demographics
(n = 140)

<table>
<thead>
<tr>
<th></th>
<th>Ttb group</th>
<th>Ctb group</th>
<th>Ctb + R group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number</td>
<td>46</td>
<td>47</td>
<td>47</td>
</tr>
<tr>
<td>% Female</td>
<td>63</td>
<td>74</td>
<td>79</td>
</tr>
<tr>
<td>% Male</td>
<td>37</td>
<td>26</td>
<td>21</td>
</tr>
<tr>
<td>Mean age</td>
<td>23</td>
<td>22</td>
<td>21</td>
</tr>
</tbody>
</table>

**Ttb** Template Test Brush.

**Ctb** Template Control Brush; **Ctb + R** Template Control Brush + CHX rinse.

Plaque

The mean plaque score data are presented in Table 2. At both follow-up assessments (interim and final), the mean, whole-mouth plaque scores of the three groups were significantly lower than the baseline scores. Comparisons of plaque scores among treatment groups showed a statistically significant \((p < 0.0001)\) difference. The CHX-Rinse group (Ctb+R) had lower plaque scores than the 2 other groups. There was no significant difference between the plaque scores of treatment groups Ttb and Ctb (see table 5).

Table 2. Mean overall plaque scores for each regimen; standard deviation in parenthesis
(n = 140)

<table>
<thead>
<tr>
<th></th>
<th>Ttb group (n = 46)</th>
<th>Ctb group (n = 47)</th>
<th>Ctb + R group (n = 47)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline†</td>
<td>1.29 (0.30)*</td>
<td>1.26 (0.22)*</td>
<td>1.16 (0.37)*</td>
<td></td>
</tr>
<tr>
<td>Interim</td>
<td>0.96 (0.35)*</td>
<td>0.90 (0.27) NS</td>
<td>0.21 (0.17) NS</td>
<td>≤0.0001**</td>
</tr>
<tr>
<td>Final</td>
<td>1.09 (0.36)</td>
<td>0.99 (0.32)</td>
<td>0.26 (0.29)</td>
<td>≤0.0001**</td>
</tr>
</tbody>
</table>

† At baseline all subjects were given a professional prophylaxis and were rendered free of plaque.

* Significant change from “baseline to interim” or from “interim to final” \((p < 0.05, Wilcoxon)\).

** Significant difference among groups (Kruskal-Wallis H-test).

NS Not significant.

**Ttb** Template Test Brush.

**Ctb** Template Control Brush; **Ctb + R** Template Control Brush + CHX rinse.
Bleeding

The mean bleeding score data are presented in Table 3. At the final examination, all treatment groups demonstrated significantly less whole-mouth bleeding as compared to the baseline scores. At both follow-up assessments (interim and final), comparison of bleeding reduction scores among treatment groups showed statistically significant ($p < 0.0001$) differences. The CHX-Rinse group (Ctb+R) had lower bleeding scores than the other two groups. There was no significant difference detected between the bleeding scores of treatment Ttb and Ctb group (see Table 5).

Table 3. Mean overall bleeding scores for each regimen; standard deviation in parenthesis ($n = 140$)

<table>
<thead>
<tr>
<th></th>
<th>Ttb group (n = 46)</th>
<th>Ctb group (n = 47)</th>
<th>Ctb + R group (n = 47)</th>
<th>$p$-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline†</td>
<td>1.26 (0.26) NS</td>
<td>1.22 (0.25)**</td>
<td>1.21 (0.24)*</td>
<td></td>
</tr>
<tr>
<td>Interim</td>
<td>1.19 (0.30)*</td>
<td>1.12 (0.24)*</td>
<td>1.03 (0.27)*</td>
<td>0.0177**</td>
</tr>
<tr>
<td>Final</td>
<td>1.03 (0.34)</td>
<td>0.95 (0.31)</td>
<td>0.74 (0.31)</td>
<td>0.0001**</td>
</tr>
</tbody>
</table>

† At the start of the study all subjects were given a professional prophylaxis and were rendered free of plaque.

* Significant change from “baseline to interim” or from “interim to final” ($p \leq 0.05$, Wilcoxon).

** Significant difference among groups (Kruskal-Wallis H-test).

NS Not significant.

Ttb Template Test Brush.

Ctb Template Control Brush; Ctb + R, Template Control Brush + CHX rinse.

Stain

The GMSI was used to evaluate whole-mouth buccal stain and is presented in Table 4. All subjects were rendered free of stain at baseline so no scores are provided.

There was a significant increase in staining in the course of the study for the three groups. At both follow-up assessments (interim and final), comparison of stain scores among treatment groups showed a statistically significant difference (see Table 4). The mean stain scores for treatment Ctb+R were statistically greater ($p=0.0001$) than for treatment Ttb and Ctb. There were no differences in stain scores between treatment Ttb and Ctb (see Table 5).
Table 4. Mean overall stain scores for each regimen; standard deviation in parenthesis

<table>
<thead>
<tr>
<th></th>
<th>Ttb group (n = 46)</th>
<th>Ctb group (n = 47)</th>
<th>Ctb + R group (n = 47)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interim</td>
<td>0.16 (0.19)*</td>
<td>0.22 (0.21)*</td>
<td>0.57 (0.39)</td>
<td>0.0001**</td>
</tr>
<tr>
<td>Final</td>
<td>1.03 (0.34)</td>
<td>0.95 (0.31)</td>
<td>0.74 (0.31)</td>
<td>0.0001**</td>
</tr>
</tbody>
</table>

At baseline all subjects were given a professional prophylaxis and were rendered free of stain (n = 140).

* Significant change from “interim to final” (p ≤ 0.05, Wilcoxon).

** Significant difference among groups (Kruskal-Wallis H-test).

NS Not significant.

Ttb Template Test Brush.

Ctb Template Control Brush; Ctb + R, Template Control Brush + CHX rinse.

Table 5. Statistical comparison between groups (n = 140, Intention to treat analysis)

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Plaque</th>
<th>Bleeding</th>
<th>Stain</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>interim</td>
<td>final</td>
<td>interim</td>
</tr>
<tr>
<td>Ttb versus Ctb</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Ttb versus Ctb + R*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Ctb versus Ctb + R</td>
<td>*</td>
<td>*</td>
<td>NS</td>
</tr>
</tbody>
</table>

*p-value ≤ 0.05.

Results of post-testing for plaque, gingivitis and stain using a Kruskal-Wallis H-test with post-testing corrected for multiple comparisons.

NS Not significant.

Ttb Template Test Brush.

Ctb Template Control Brush; Ctb + R, Template Control Brush + CHX rinse.

Oral Tissues

No differences were detected in the proportion of oral tissue abnormalities among the groups, with the exception of the tongue. Changes noted were the presence of stain or discoloration on the tongue. Treatment Ctb+R yielded a statistically significantly (p=0.0001) greater proportion of abnormal observations than treatments Ttb and Ctb.
Discussion

The present study evaluated whether the effect of toothbrushing could be enhanced by the use of CHX. The CHX digluconate was slowly released from the head of a newly-designed experimental toothbrush when brought into contact with oral fluids. The Ttb (template test brush) and the Ctb (template control brush) were modified Oral B Advantage toothbrushes. CHX mouthrinse was used as a positive control in combination with the Ctb. A positive control compares and positions the efficacy of a test product and is frequently used in oral hygiene study protocols (Addy 1986, Addy 1995). Within the limitations of the present study, no beneficial effect could be demonstrated for this prototype product.

The outcome of the present study is not in agreement with earlier clinical studies, which have attempted to improve the effects of toothbrushing with the use of different CHX agents. Some have employed a CHX gel for toothbrushing, while others have dipped the brushes in a CHX solution. Bassiouny & Grant (1975) used a 1% CHX gel for toothbrushing twice daily for six weeks, which resulted in a statistically significant drop in plaque and gingivitis scores, as compared to the use of placebo gel. Bay (1978) showed that twice daily brushing with a toothbrush which had been immersed in a CHX solution, prevented plaque formation and the development of gingivitis, even with low CHX concentrations (0.15%, 0.10% and 0.05%). Flötra (1973) and Usher (1975) have reported that 1% CHX gel, when used by mentally and physically disabled people with a very low standard of mechanical cleaning, had a therapeutic effect on gingival conditions. Epstein et al. (1994) and Ransier et al. (1995) concluded that a foam brush, which is usually ineffective in controlling plaque levels and gingivitis (Addems et al. 1992), could improve the gingival conditions as effectively as a toothbrush when the foam brush is soaked in 0.2% CHX. In other studies, however, CHX active gel did not markedly influence plaque formation and gingival conditions (Emilson & Fornell 1976, Saxen et al. 1976, Hansen et al. 1975, Bain & Strahan 1978).

Contradictions in existing literature may have their origins in several factors, such as the presence of a baseline prophylaxis, the level of plaque control, the concentration of CHX and the brushing frequency. In those studies where initial prophylaxis sessions and extensive instructions in oral hygiene were carried out, a positive effect of toothbrushing with CHX was noted (Bassiouny & Grant 1975, Bay 1978, Epstein et al.1994, Ransier et al.1995). However, if the participants were not free of plaque initially and no attempts were made to remove subgingival plaque or calculus intermittently, the adjunctive effect of CHX appeared to be minimal (Hansen et al. 1975, Emilson & Fornell 1976). In the present study, therefore, at baseline,
prophylaxis and professional oral hygiene instructions were provided in order to obtain the optimal benefit from the active CHX agent. In this respect it is surprising that no beneficial chemotherapeutic effect on the gingival conditions was found. The most likely explanation seems the dose release profile of the active agent from the brush head. In comparison, rinsing for 60 seconds with 10 ml of a 0.2% CHX-digluconate solution provides a dose of 20 mg which is able to inhibit plaque regrowth and to prevent inflammation of the gums (Löe & Schiött 1970). Concentrations of 0.12% CHX appear as effective as 0.2% if the volume of the rinse was increased from 10 to 15 ml, giving an 18 mg dose on each occasion (Keijser et al. 2003). Following Bassioumy & Grant (1975), even a lowered dose of 5 mg CHX in a 1% gel was found to be effective. Stoeken et al. (2007) described that 3.2 mg of a 0.12% CHX spray has a plaque reducing effect. In the present study, the maximum dose of CHX per brushing was 5.04 mg (after 2nd brushing). With an average release per brushing of 1.3 mg the test brush did not provide any beneficial effect in addition to mechanical plaque removal. Based on these findings, future developments could focus on an elevated amount of CHX per brushing and a more regular release pattern over time.

Although no benefit could be shown for the use of the CHX template toothbrush, the positive control group, which combined one minute toothbrushing without dentifrice and rinsing for 60 seconds twice daily with 10 ml of 0.2% CHX (20 mg dose), confirms the results of earlier studies (Löe & Schiött 1970, Gjermo et al. 1970, Bay 1978) and remains an effective treatment for the control of plaque and gingivitis. Thus a CHX rinse in combination with toothbrushing can provide an adequate therapeutic effect where additional efficacy is needed to control plaque and gingivitis. It has been suggested in the past that toothbrushing with an SLS-containing dentifrice may inhibit the effect of CHX (Barkvoll et al. 1989, Owens et al. 1997). Recent studies, however, have clearly shown that ordinary toothbrushing with an SLS-containing dentifrice before or after the use of CHX, does not reduce the anti-plaque efficacy of the rinse (Van Strydonck et al. 2004 a,b, Van Strydonck et al. 2006).

In the present study, there was statistically more dental staining in the three groups compared to baseline. For the groups using CHX, Ttb and Ctb+R, this is in agreement with the results of earlier studies (Flöttra et al. 1971, Addy et al. 1991, Gründemann et al. 2000). However, since only the Ttb group used a toothbrush which released CHX, the small difference in staining between the Ttb group and the Ctb group (without CHX-release) was rather unexpected. The higher staining score in the Ctb group may be explained by the fact that no dentifrice was used. Although dentifrice does not primarily result ‘instant’ mechanical plaque
removal (Paraskevas et al. 2006), brushing with dentifrice is traditionally recommended for the prevention of staining (Lobene 1968, Forward 1991).

Within the limitations of the present study, no beneficial effect could be demonstrated for the prototype CHX releasing toothbrush. Whilst studies continue to search for the most convenient and clinically effective way of delivering additional chemical plaque control, the use of a 0.2% CHX mouthrinse (in combination with toothbrushing) remains the gold standard.

Acknowledgments

The authors would like to thank Yvonne IJzerman (YIJ) and Mahé Piscaer (MP) for their help in conducting this study, Frances Doherty from Oral-B Laboratories USA as Manager of this Clinical Research project and Gerben Dreijer from GlaxoSmithKline Consumer Healthcare for providing the Corsodyl® mouthrinse.
References


